Determination of carboplatin in canine plasma by high‐performance liquid chromatography

Carboplatin is an antineoplastic drug administered to treat different tumoral conditions in canine oncology. The objective of this study was to validate a high‐performance chromatographic (HPLC) method which could be applied in canine pharmacokinetic studies. Following ultrafiltration using a Centrifree device, standards, quality controls and plasma samples were separated by isocratic reversed‐phase HPLC on an Inertsil ODS‐2 (250 × 4.6 mm i.d.) analytical column and quantified using UV detection at 220 nm. The mobile phase was potassium phosphate (pH 4.5), with a flow‐rate of 1.0 mL/min. The procedure produced a linear curve ( r 2 > 0.999) over the concentration range 1–200 μg/mL. The lower limit of quantification was 1 μg/mL. The intra‐assay and inter‐assay precision was ∼90%. The overall recovery was ∼90%. The method was illustrated with a preliminary pharmacokinetic analysis on nine dogs treated with carboplatin at our hospital. Carboplatin disposition followed a monocompartmental structure in dogs and was characterized by a short half‐life (50 min). Copyright © 2009 John Wiley & Sons, Ltd.